Trials / Active Not Recruiting
Active Not RecruitingNCT01797055
Apotransferrin in Atransferrinemia
Dose Escalating Study to Evaluate Pharmacokinetics, Efficacy and Safety of Apotransferrin in Atransferrinemia Patients
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Prothya Biosolutions · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Atransferrinemia is a very rare disorder, which is caused by a deficiency of the protein transferrin. No regular treatment is available for these patients. The objective of this study is to investigate the pharmacokinetics, efficacy and safety of Apotransferrin replacement therapy in atransferrinemia patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Human apotransferrin | intravenous infusion |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2022-03-31
- Completion
- 2028-01-01
- First posted
- 2013-02-22
- Last updated
- 2025-08-03
Locations
3 sites across 3 countries: Germany, Italy, Spain
Source: ClinicalTrials.gov record NCT01797055. Inclusion in this directory is not an endorsement.